Athyrium Opportunities Fund II (AOF II)

Athyrium Opportunities Fund II1

Company Marketer / Counterparty Product Initial Investment Date
Zealand Pharma A/S Sanofi Lyxumia January 2015
Valneva SE Valneva, Various Partners Various Vaccines and Vaccine Technology Platforms January 2015
Apollo Endosurgery, Inc. Apollo Endosurgery, Inc. Minimally Invasive Medical Devices for Obesity February 2015
Indivior PLC Indivior PLC Suboxone, other addiction treatments March 2015
Cipher Pharmaceuticals, Inc. Cipher Pharmaceuticals, Inc., Ranbaxy Laboratories Various Pharmaceuticals, Primarily Dermatology Focused April 2015
Novelion Therapeutics, Inc. Novelion Therapeutics, Inc. Orphan Pharmaceuticals July 2015
AMAG Pharmaceuticals, Inc. AMAG Pharmaceuticals, Inc. Makena, Feraheme, Cord Blood Registry August 2015
HLS Therapeutics, Inc. HLS Therapeutics, Inc. CLOZARIL® August 2015
Clover Health, Inc. Clover Health, Inc. Heath Insurance (Medicare Advantage Plans) September 2015
Horizon Pharma plc Horizon Pharma plc Orphan, Primary Care, Specialty Pharmaceuticals October 2015
US WorldMeds Ventures LLC US WorldMeds Ventures LLC Various Specialty Pharmaceuticals November 2015
Bionpharma Inc. Bionpharma Inc. & Various Marketing Partners Specialty Generics December 2015
Lannett Company, Inc. Lannett Company, Inc. Generic Pharmaceuticals December 2015
Halozyme Royalty LLC Roche and Baxalta Herceptin SC, MabThera SC, and HyQvia January 2016
Alcresta, Inc. Alcresta, Inc. Relizorb March 2016
Alvogen Alvogen Specialty Generics April 2016
Relypsa, Inc. Relypsa, Inc., Vifor Fresenius Medical Care Renal Pharma Ltd. Veltassa® (patiromer) May 2016
Arbor Pharmaceuticals LLC Arbor Pharmaceuticals LLC Various Specialty Pharmaceuticals July 2016
Medicrea International Medicrea International UNiD Patient-Specific Rods August 2016
Pharmaceutics International, Inc. Pharmaceutics International, Inc. Contract Development and Manufacturing Organization August 2016
Highland Acquisition Holdings, LLC (HealthSun) HealthSun Health Plans Inc. Medicare Advantage Health Plan and Integrated Care Delivery System November 2016
PTC Therapeutics, Inc. PTC Therapeutics, Inc. Orphan Pharmaceuticals November 2016
Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc., Various Partners Amitiza December 2016
VIVUS, Inc. VIVUS, Inc. Qsymia and STENDRA/SPEDRA March 2017

1. This table lists all investments made by the Athyrium Opportunities Fund II.